Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501

NCT05717153 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT05717153
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05717153 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501
Lead sponsor
Mayo Clinic
Phase
Phase 1
Overall status
Recruiting
Start date
October 1, 2023
Completion date
September 15, 2027
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse glioma, malignant glioma